West Pharmaceutical Services (WST)
(Delayed Data from NYSE)
$302.78 USD
+2.26 (0.75%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $302.74 -0.04 (-0.01%) 7:58 PM ET
5-Strong Sell of 5 5
F Value C Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$302.78 USD
+2.26 (0.75%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $302.74 -0.04 (-0.01%) 7:58 PM ET
5-Strong Sell of 5 5
F Value C Growth D Momentum F VGM
Zacks News
Cooper Companies (COO) Q3 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Cooper Companies' (COO) fiscal third-quarter earnings reflect solid segmental performance.
Patterson Companies (PDCO) Q1 Earnings & Revenues Top Estimates
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal first-quarter 2022 results benefit from strong segmental performance.
Veeva Systems (VEEV) Q2 Earnings Beat Estimates, '22 View Up
by Zacks Equity Research
Veeva Systems' (VEEV) fiscal Q2 results reflect impressive performances by both its segments.
Catalent's (CTLT) Q4 Earnings Top Estimates, Margins Rise
by Zacks Equity Research
Catalent's (CTLT) robust performance across the majority of its segments drives its fourth-quarter fiscal 2021 top line.
Cooper Companies (COO) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Cooper Companies' (COO) fiscal third-quarter results are likely to reflect segmental strength.
Phibro (PAHC) Q4 Earnings Match Estimates, Margins Down
by Zacks Equity Research
Phibro (PAHC) sees revenue growth in fourth-quarter fiscal 2021 due to strength in all three segments.
What's in Store for Patterson Companies' (PDCO) Q1 Earnings?
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal first-quarter results are likely to reflect improvement at Dental segment.
Is West Pharmaceutical Services (WST) a Great Growth Stock?
by Zacks Equity Research
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider West Pharmaceutical Services (WST).
Here is Why Growth Investors Should Buy West Pharmaceutical (WST) Now
by Zacks Equity Research
West Pharmaceutical (WST) could produce exceptional returns because of its solid growth attributes.
Align Technology (ALGN) at a 52-Week High: What's Driving It?
by Zacks Equity Research
Strong performance by the Clear Aligners and Systems & CAD/CAM Services segments drove the top line for Align Technology (ALGN).
Medtronic's (MDT) Q1 Earnings Beat Estimates, Margins Up
by Zacks Equity Research
Medtronic's (MDT) fiscal first-quarter results reflect a strong recovery from the impact of the COVID-19 pandemic on elective procedures that the company experienced in 2020.
The Zacks Analyst Blog Highlights: Microsoft, EMCOR, West Pharmaceutical Services, Deere and Texas Instruments
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Microsoft, EMCOR, West Pharmaceutical Services, Deere and Texas Instruments
Here's Why You Should Add Omnicell (OMCL) to Your Portfolio
by Zacks Equity Research
Omnicell (OMCL) ended the second quarter with better-than-expected results, with the top line registering solid year-over-year growth.
Here's Why You Should Invest in West Pharmaceutical (WST) Now
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum on the back of strength in Proprietary Products business.
LabCorp (LH) Inks Deal to Assess Disparities in Drug Development
by Zacks Equity Research
LabCorp (LH) and CCORN partner to develop a patient registry and biobank to help design cancer clinical trials in diverse populations.
Sustainability Trends Boost ESG Investing: 5 Green Picks
by Sreoshi Bera
ESG investing will get a boost from sustainability trends, which calls for investing in Microsoft (MSFT), EMCOR Group (EME), West Pharmaceutical (WST), Deere (DE) & Texas Instruments (TXN).
West Pharmaceutical (WST) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about West Pharmaceutical's (WST) robust proprietary products segment and its continued strength in R&D.
Alcon (ALC) Q2 Earnings Top Estimates, 2021 Guidance Up
by Zacks Equity Research
Alcon (ALC) records the highest sales in the second quarter of 2021 since its spin-off.
West Pharmaceutical (WST) Moves to Strong Buy: Rationale Behind the Upgrade
by Zacks Equity Research
West Pharmaceutical (WST) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here's Why You Should Hold on to PerkinElmer (PKI) Stock Now
by Zacks Equity Research
PerkinElmer (PKI) continues to gain momentum on the back of a solid product portfolio and improving margins. However, forex woes linger.
National Vision (EYE) Q2 Earnings Top Estimates, 2021 View Up
by Zacks Equity Research
Strength in Americas Best and Eyeglass World brands drove National Vision's (EYE) revenues in the second quarter of 2021.
Accuray (ARAY) Posts In-Line Q4 Earnings, Beats on Revenues
by Zacks Equity Research
Accuray (ARAY) registers growth in Service and Product revenues during fiscal Q4.
Here's Why You Should Invest in Intuitive Surgical (ISRG) Now
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to gain traction from improving adoption of da Vinci Surgical System.
Haemonetics (HAE) Q1 Earnings Top Estimates, Margins Improve
by Zacks Equity Research
Ongoing recovery in businesses, especially Hospital, and the initial Plasma Persona rollouts drove Haemonetics (HAE) fiscal first-quarter revenues.
Inari Medical (NARI) Q2 Earnings Lag, Revenues Top Estimates
by Zacks Equity Research
Inari Medical's (NARI) second-quarter 2021 results benefit from significant revenue growth and gross margin expansion.